|
FGF18 |
fibroblast growth factor 18 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Signaling by activated point mutants of FGFR3
- FGFR4 ligand binding and activation
- FGFR3b ligand binding and activation
- FGFR3c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR3 mutant receptor activation
- Activated point mutants of FGFR2
- Constitutive Signaling by Aberrant PI3K in Cancer
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR3
- Phospholipase C-mediated cascade; FGFR4
- PI-3K cascade:FGFR2
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- PI-3K cascade:FGFR4
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Signaling by FGFR2 in disease
- FGFRL1 modulation of FGFR1 signaling
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by FGFR3 point mutants in cancer
|
|
|
|
FGF2 |
fibroblast growth factor 2 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Signaling by activated point mutants of FGFR1
- Signaling by activated point mutants of FGFR3
- FGFR4 ligand binding and activation
- FGFR1b ligand binding and activation
- FGFR3c ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR2b ligand binding and activation
- FGFR3 mutant receptor activation
- Activated point mutants of FGFR2
- Constitutive Signaling by Aberrant PI3K in Cancer
- POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
- Syndecan interactions
- Non-integrin membrane-ECM interactions
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR3
- Phospholipase C-mediated cascade; FGFR4
- Downstream signaling of activated FGFR1
- SHC-mediated cascade:FGFR1
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Signaling by FGFR2 in disease
- Signaling by FGFR1 in disease
- FGFRL1 modulation of FGFR1 signaling
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by FGFR2 IIIa TM
- Signaling by FGFR3 point mutants in cancer
|
- Sucralfate
- Pentosan polysulfate
- Sirolimus
- Heparin
- 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
- N,O6-Disulfo-Glucosamine
- 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
- ABT-510
|
|
|
FGF3 |
fibroblast growth factor 3 |
- PI3K Cascade
- PIP3 activates AKT signaling
- FGFR1b ligand binding and activation
- FGFR2b ligand binding and activation
- Activated point mutants of FGFR2
- Constitutive Signaling by Aberrant PI3K in Cancer
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Downstream signaling of activated FGFR1
- SHC-mediated cascade:FGFR1
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Signaling by FGFR2 in disease
- FGFRL1 modulation of FGFR1 signaling
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
|
|
|
FGF4 |
fibroblast growth factor 4 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Signaling by activated point mutants of FGFR1
- Signaling by activated point mutants of FGFR3
- FGFR4 ligand binding and activation
- FGFR3c ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR3 mutant receptor activation
- Activated point mutants of FGFR2
- Constitutive Signaling by Aberrant PI3K in Cancer
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR3
- Phospholipase C-mediated cascade; FGFR4
- Downstream signaling of activated FGFR1
- SHC-mediated cascade:FGFR1
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Signaling by FGFR2 in disease
- Signaling by FGFR1 in disease
- FGFRL1 modulation of FGFR1 signaling
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by FGFR3 point mutants in cancer
|
- Pentosan polysulfate
- Heparin
- TP-508
|
|
|
FGF5 |
fibroblast growth factor 5 |
|
|
|
|
FGF6 |
fibroblast growth factor 6 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Signaling by activated point mutants of FGFR1
- FGFR4 ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- Activated point mutants of FGFR2
- Constitutive Signaling by Aberrant PI3K in Cancer
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR4
- Downstream signaling of activated FGFR1
- SHC-mediated cascade:FGFR1
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR4 signaling
- Signaling by FGFR2 in disease
- Signaling by FGFR1 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
|
|
|
FGF7 |
fibroblast growth factor 7 |
- PI3K Cascade
- PIP3 activates AKT signaling
- FGFR2b ligand binding and activation
- Activated point mutants of FGFR2
- Constitutive Signaling by Aberrant PI3K in Cancer
- Phospholipase C-mediated cascade; FGFR2
- PI-3K cascade:FGFR2
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- Negative regulation of FGFR2 signaling
- Signaling by FGFR2 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
|
|
|
FGF8 |
fibroblast growth factor 8 |
|
|
- Hypogonadotropic hypogonadism; Kallmann syndrome (KAL)
|
|
FGF9 |
fibroblast growth factor 9 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Signaling by activated point mutants of FGFR1
- Signaling by activated point mutants of FGFR3
- FGFR4 ligand binding and activation
- FGFR3b ligand binding and activation
- FGFR3c ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR3 mutant receptor activation
- Activated point mutants of FGFR2
- Constitutive Signaling by Aberrant PI3K in Cancer
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR3
- Phospholipase C-mediated cascade; FGFR4
- Downstream signaling of activated FGFR1
- SHC-mediated cascade:FGFR1
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Signaling by FGFR2 in disease
- Signaling by FGFR1 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by FGFR3 point mutants in cancer
- Transcriptional regulation of testis differentiation
|
|
|
|
FLRT3 |
fibronectin leucine rich transmembrane protein 3 |
- Signaling by ROBO receptors
- Downstream signaling of activated FGFR1
|
|
|
|
FRS2 |
fibroblast growth factor receptor substrate 2 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Frs2-mediated activation
- Frs2-mediated activation
- Constitutive Signaling by Aberrant PI3K in Cancer
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- FRS-mediated FGFR2 signaling
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by FGFR3 fusions in cancer
- Signaling by FGFR3 point mutants in cancer
- RET signaling
- Activated NTRK2 signals through FRS2 and FRS3
- Activated NTRK2 signals through FRS2 and FRS3
|
|
|
|
FRS3 |
fibroblast growth factor receptor substrate 3 |
- FRS-mediated FGFR1 signaling
- FRS-mediated FGFR2 signaling
- FRS-mediated FGFR3 signaling
- FRS-mediated FGFR4 signaling
- RAF/MAP kinase cascade
- Activated NTRK2 signals through FRS2 and FRS3
|
|
|
|
GRB14 |
growth factor receptor bound protein 14 |
|
|
|
|
GRB2 |
growth factor receptor bound protein 2 |
- Interleukin-15 signaling
- Interleukin-15 signaling
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
|
- Pegademase
- 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
|
|
|
HTR1A |
5-hydroxytryptamine receptor 1A |
|
- Eletriptan
- Ziprasidone
- Methysergide
- Cabergoline
- Zolmitriptan
- Amitriptyline
- Olanzapine
- Clozapine
- Loxapine
- Pramipexole
- Methylphenidate
- Imipramine
- Chlorpromazine
- Buspirone
- Haloperidol
- Nortriptyline
- Amoxapine
- Propranolol
- Fenfluramine
- Lisuride
- Trazodone
- Sumatriptan
- Ergotamine
- Apomorphine
- Paroxetine
- Trimipramine
- Risperidone
- Alprenolol
- Ondansetron
- Naratriptan
- Pindolol
- Dopamine
- Ergoloid mesylate
- Doxepin
- Nefazodone
- Desipramine
- Escitalopram
- Pergolide
- Bromocriptine
- Ketamine
- Quetiapine
- Aripiprazole
- Chlorprothixene
- Paliperidone
- Penbutolol
- Yohimbine
- Acepromazine
- Alverine
- Molindone
- Pipotiazine
- Thioproperazine
- Lysergic acid diethylamide
- Dapoxetine
- Bifeprunox
- Flibanserin
- Iloperidone
- Lofexidine
- Lesopitron
- Rotigotine
- MN-305
- LI-301
- Naluzotan
- Cariprazine
- Mianserin
- Pizotifen
- Asenapine
- Xaliproden
- Dotarizine
- Sarizotan
- Repinotan
- Robalzotan
- Vilazodone
- Bopindolol
- Cinitapride
- Lurasidone
- Perospirone
- Cannabidiol
- Vortioxetine
- Brexpiprazole
- Dosulepin
- Pirlindole
- Tianeptine
- Setiptiline
- Dihydroergocornine
- Tetrahydrocannabivarin
- Pardoprunox
- Gilteritinib
- Tiapride
- Dihydroergocristine
- Medical Cannabis
- 5-methoxy-N,N-dimethyltryptamine
- Nabiximols
- Aripiprazole lauroxil
- SEP-363856
|
|
|
HULC |
hepatocellular carcinoma up-regulated long non-coding RNA |
|
|
|
|
IL17RD |
interleukin 17 receptor D |
- MAP2K and MAPK activation
|
|
|
|
ITGB3 |
integrin subunit beta 3 |
- Platelet degranulation
- Elastic fibre formation
- PECAM1 interactions
- Molecules associated with elastic fibres
- Integrin cell surface interactions
- Integrin cell surface interactions
- Syndecan interactions
- Syndecan interactions
- ECM proteoglycans
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- VEGFA-VEGFR2 Pathway
- Signal transduction by L1
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
|
- Abciximab
- Eptifibatide
- Antithymocyte immunoglobulin (rabbit)
- Levothyroxine
- Tirofiban
- Resveratrol
- Lefradafiban
- LM-609
- Fradafiban
- Ferric maltol
|
- Glanzmann thrombasthenia
- Allograft rejection
|
|
ITK |
IL2 inducible T cell kinase |
- Generation of second messenger molecules
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
|
- Staurosporine
- Pazopanib
- Fostamatinib
- Zanubrutinib
|
|
|
KLB |
klotho beta |
- PI3K Cascade
- PIP3 activates AKT signaling
- betaKlotho-mediated ligand binding
- Constitutive Signaling by Aberrant PI3K in Cancer
- Phospholipase C-mediated cascade; FGFR4
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- PI-3K cascade:FGFR4
- Negative regulation of FGFR4 signaling
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
|
|